Related Experiment Video
Updated: Feb 14, 2026

The Measurement and Treatment of Suppression in Amblyopia
Published on: December 14, 2012
A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment
Burçin Çelik1, Zeynep Pelin Sürücü1, Volkan Yılmaz1
1Department of Thoracic Surgery, Ondokuz Mayıs University School of Medicine, Samsun, Turkey.
Abstract:
Secondary spontaneous pneumothorax almost always develops secondary to an underlying lung disease. A pneumothorax secondary to a malignancy is very rare, and is observed most frequently in soft tissue sarcomas. Pazopanib, a tyrosine kinase inhibitor, is used in metastatic soft tissue sarcomas treatment. The rate of pneumothorax that is caused by pazopanib is about 14% in the literature. The patient being presented in this article underwent surgery for soft tissue sarcoma, postoperatively received pazopanib (Votrient® 400 mg, oral, Glaxo Group Ltd, Brentford, UK) treatment due to widespread bilateral lung metastases, and developed synchronous spontaneous pneumothorax.
More Related Videos
05:50International Expert Consensus and Recommendations for Neonatal Pneumothorax Ultrasound Diagnosis and Ultrasound-guided Thoracentesis Procedure
Published on: March 12, 2020
07:03Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice
Published on: July 31, 2019
Related Concept Videos
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax-II
Clinical Manifestations:
Secondary Active Transport
Secondary Active Transport
Secondary Healthcare System
Primary and Secondary Growth in Roots and Shoots